Inmune Bio (INMB) EBIAT (2018 - 2025)
Inmune Bio (INMB) has disclosed EBIAT for 8 consecutive years, with -$5.2 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 43.25% to -$5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45.9 million through Dec 2025, down 9.07% year-over-year, with the annual reading at -$45.9 million for FY2025, 9.07% down from the prior year.
- EBIAT hit -$5.2 million in Q4 2025 for Inmune Bio, up from -$6.5 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$4.6 million in Q1 2021 to a low of -$24.5 million in Q2 2025.
- Historically, EBIAT has averaged -$8.8 million across 5 years, with a median of -$8.1 million in 2022.
- Biggest five-year swings in EBIAT: plummeted 215.7% in 2021 and later surged 46.48% in 2025.
- Year by year, EBIAT stood at -$9.7 million in 2021, then soared by 39.69% to -$5.8 million in 2022, then crashed by 44.01% to -$8.4 million in 2023, then dropped by 9.74% to -$9.2 million in 2024, then surged by 43.25% to -$5.2 million in 2025.
- Business Quant data shows EBIAT for INMB at -$5.2 million in Q4 2025, -$6.5 million in Q3 2025, and -$24.5 million in Q2 2025.